Managed Healthcare Executive December 4, 2023
A recent study has found that FDA inspections of drug manufacturing facilities have increased since the COVID-19 health emergency but have not yet returned to pre-pandemic numbers.
The COVID-19 pandemic impacted the FDA’s ability to properly inspect facilities that manufacture prescription drugs, which could have impacted drug quality, suggests a new paper in the December 2023 issue of Health Economics. Even now after the public health emergency has lifted, the authors said concerns about drug quality remain as regulators work through their backlog of inspections, especially in foreign facilities.
Prescription drug manufacturing outside the United States plays a critical role in the U.S. supply of medications, with India, China and Italy playing a lead role in manufacturing active ingredients.
During...
Today's Sponsors
Today's Sponsor